Clinical trials: Insulin
Growth Hormone Disorder, Pituitary Dwarfism
Somatropin (Norditropin) in Insulin-like Growth Factor (IGF) Deficient Children
This trial is conducted in the United States of America (USA). This is a 12 month study to determine if Norditropin is safe and effective in children with IGF deficiency.
- Trial name
- NCT00102817
- Testing
- somatropin
- Where
- 27 sites in United States
- Volunteers
- 149 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1
Observational Study of Patients Using NovoMix® 30 or Levemir® for Treatment of Type 1 or Type 2 Diabetes
This trial is conducted in Europe. The aim of this observational study is to evaluate the glycaemic control in patients with type 1 or 2 diabetes using NovoMix® 30 or Levemir® under normal clinical practice conditions.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT00671008
- Testing
- biphasic insulin aspart 30, insulin detemir
- Where
- Bosnia and Herzegovina
- Volunteers
- 400 people
- Sponsor
- Novo Nordisk A/S
IGF-1 Deficiency
IGF-1, IGFBP3, ALS Normative Ranges in Healthy Pediatric Spanish Population
To determine the normative ranges of the Insulin-like Growth Factor 1 (IGF-1), Insulin-like growth factor-binding protein 3 (IGFBP-3), Acid-Labile Subunit (ALS) according to age, sex and pubertal stage of a healthy paediatric…
- Trial name
- EDISON (NCT01676090)
- Where
- 9 sites in Spain
- Volunteers
- 304 people, healthy volunteers welcome
- Sponsor
- Ipsen
Diabetes, Diabetes Mellitus, Type 2
Physiological Concept of Insulin Therapy in Subjects With Type 2 Diabetes
This study is conducted in Europe. The aim of the study was to evaluate the safety and efficacy of biphasic insulin aspart 30 (NovoMix® 30) when switching to a modern premix insulin analogue treatment compared to previous insulin…
- Trial name
- NCT01536639
- Testing
- biphasic insulin aspart 30
- Where
- Slovakia
- Volunteers
- 454 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes, Type 2 Diabetes
A Prospective, Randomized, Parallel Crossover Study Demonstrating Subject Wearability and Usability of the I-Port Injection Port
This study investigated wearability and usability of the I-PORT™ Injection Port (I-PORT™), a new disposable injection port through which prescribed medication is injected subcutaneously from a standard syringe or pen.
- Trial name
- NCT00486109
- Testing
- I-Port(TM) Injection Port
- Where
- 5 sites in United States
- Volunteers
- 74 people
- Sponsor
- Patton Medical Devices
Type 1 Diabetes Mellitus
A Phase III Study to Investigate if the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed With Type 1 Diabetes
The objective of DIAGNODE-3 is to evaluate the efficacy and safety of three intranodal injections of 4 μg of Diamyd also known as retogatein compared to placebo, along with oral Vitamin D supplementation, to preserve endogenous…
- Trial name
- DIAGNODE-3 (NCT05018585)
- Testing
- Recombinant human glutamic acid decarboxylase (rhGAD65) formulated in Alhydrogel®, Colecalciferol 2000 IU
- Where
- 60 sites in United States, Czechia and 7 more
- Volunteers
- 321 people
- Sponsor
- Diamyd Medical AB
Type 1 Diabetes, Type 2 Diabetes
User Evaluation of the MiniMed 640G Insulin Pump
This four center international study will include two United Kingdom National Health Service centers, and two centers in Melbourne, Australia.
- Trial name
- NCT01991548
- Testing
- MiniMed® 640G Insulin Pump and Guardian® Link Transmitter
- Where
- 4 sites in Australia, United Kingdom
- Volunteers
- 52 people
- Sponsor
- Medtronic MiniMed, Inc.
Diabetes Mellitus, Type 1
Safety And Efficacy Of Exubera Compared With Subcutaneous Human Insulin Therapy In Children And Adolescents
To assess the safety and efficacy of Exubera on pulmonary function and glycemic control in subjects ages 6-17 over a 1 year period.
- Trial name
- NCT00479258
- Testing
- Inhaled insulin (Exubera), Subcutaneous Insulin (subject's prescribed)
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Pfizer
Diabetes, Diabetes Mellitus, Type 2
Observational Study of Safety and Effectiveness of NovoMix® 30 for the Treatment of Diabetes
This study is conducted in Asia, Europe, Japan and North America. The aim of this observational study is to evaluate the safety and effectiveness while using NovoMix® 30 during 26 weeks under normal clinical practice, in the…
- Trial name
- IMPROVE™ (NCT00659282)
- Testing
- biphasic insulin aspart
- Where
- 11 sites in Canada, China and 9 more
- Volunteers
- 57,610 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1
Observational Study on Levemir® in Obese Diabetic Patients
This study is conducted in Europe. The aim of this observational study is to investigate the effect of switch from other basal insulin treatments to Levemir® on body weight in obese diabetic patients.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- KILOS (NCT00849342)
- Testing
- insulin detemir
- Where
- 2 sites in Netherlands, Slovenia
- Volunteers
- 580 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus
Compare Blood Sugar Level Between Lantus in the Morning and Other Insulins in Type 1 Diabetes Adolescents
The purpose of the study is to compare the effect in blood sugar control between Lantus and twice daily intermediate acting insulins (NPH or Lente) when used as the basal insulin in a multiple daily injection setting with fast…
- Trial name
- NCT00046501
- Testing
- Lantus (insulin glargine [rDNA origin] injection), Humulin N, Humulin L
- Where
- United States
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Sanofi
Diabetes, Diabetes Mellitus, Type 2
Observational Study to Assess the Quality of Life and Clinical Outcomes in Subjects Using NovoMix® 30 for the Treatment of Diabetes
This study is conducted in Asia. The aim of this observational study is to evaluate the quality of life and clinical outcomes in subjects using NovoMix® 30 (biphasic insulin aspart 30) for the treatment of diabetes mellitus under…
- Trial name
- IMPROVE Life (NCT00696163)
- Testing
- biphasic insulin aspart 30
- Where
- India
- Volunteers
- 24,975 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes Mellitus
Pediatric Diabetics Type 1 Using InsuPatch
This study is a prospective, single-center, open label, randomized; two-arms cross over study. This is the test protocol for the InsuPatch device, whose purpose is to improve insulin delivery into the blood when the insulin is…
- Trial name
- NCT01368978
- Testing
- InsuPatch
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Insuline Medical Ltd.
Type 1 Diabetes Mellitus
A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (USA)- DIAPREVENT
The intended purpose of this study was to determine whether Diamyd (rhGAD65 formulated in alum) is effective in preserving the body's own insulin producing capacity in patients recently diagnosed with type 1 diabetes.
- Trial name
- NCT00751842
- Testing
- rhGAD65
- Where
- 43 sites in United States
- Volunteers
- 331 people
- Sponsor
- Diamyd Therapeutics AB
Type 1 Diabetes
PS230005 Control-IQ 1.5 Post-Approval Study
This 522 post-market surveillance study is a single-arm, decentralized prospective observational cohort study designed to collect safety data on Control-IQ technology v1.5 in children with type 1 diabetes ages 2 to <6 years old.
- Trial name
- NCT06717451
- Testing
- Control-IQ Technology v1.5
- Where
- United States
- Volunteers
- 144 people
- Sponsor
- Tandem Diabetes Care, Inc.
Type 1 Diabetes
In Clinic Evaluation of the PLGM Feature
This study is a multi-center, single arm and in-clinic study to evaluate the safety of the PLGM System and its algorithm with the Enlite 3 Sensor.
- Trial name
- PLGM (NCT02130284)
- Testing
- Predictive Low Glucose Management Feature in Insulin pump
- Where
- 8 sites in United States
- Volunteers
- 80 people
- Sponsor
- Medtronic MiniMed, Inc.
Diabetes, Diabetes Mellitus, Type 1
Post Marketing Surveillance Study of Biphasic Insulin Aspart 30
This study is conducted in Asia. The aim of this study is to review the safety and efficacy of biphasic insulin aspart 30 in post-marketing use.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT01536613
- Testing
- biphasic insulin aspart 30
- Where
- South Korea
- Volunteers
- 5,346 people
- Sponsor
- Novo Nordisk A/S
Primary Insulin-like Growth Factor-1 Deficiency
IGFD Registry: A Patient Registry for Monitoring Long-term Safety and Efficacy of Increlex
This project is a retrospective (beginning January 2006) and prospective patient registry program sponsored by Ipsen (formerly Tercica, Inc.).
- Trial name
- NCT00747604
- Testing
- mecasermin [rDNA origin] injection
- Where
- United States
- Volunteers
- 1,378 people
- Sponsor
- Ipsen
Diabetes, Diabetes Mellitus, Type 1
Evaluation of Levemir® for the Treatment of Type 1 and 2 Diabetes
This study is conducted in Europe. The aim of this observational study is to evaluate the incidence of serious adverse drug reactions while using Levemir® under normal clinical practice conditions.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- PREDICTIVE™ (NCT00655044)
- Testing
- insulin detemir
- Where
- Russia
- Volunteers
- 3,637 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes
Insulet Artificial Pancreas Early Feasibility Study
The purpose is to perform an early investigation on the safety and performance of an Automated Glucose Control (AGC) algorithm using the OmniPod® Insulin Management System and gather clinical data that will be used to make…
- Trial name
- NCT02897557
- Testing
- Insulet Artificial Pancreas (AP) System
- Where
- 4 sites in United States
- Volunteers
- 59 people
- Sponsor
- Insulet Corporation